vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease. Its drug candidates also include TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase 2b clinical trials for the treatment of type 2 diabetes, as well as initiated Phase 1b/2 clinical trials for the treatment of type 1 diabetes; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. vTv Therapeutics Inc. has a license and research agreement with Calithera Biosciences, Inc. to develop and commercialize its hexokinase II inhibitors for therapeutic, prophylactic, preventative, or diagnostic use. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of vTv Therapeutics Holdings LLC.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Phone336-841-0300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$12.43 million
Profitability
Miscellaneous
Employees52
Next Earnings Date5/21/2019 (Estimated)
OptionableNot Optionable
vTv Therapeutics (NASDAQ:VTVT) Frequently Asked Questions
What is vTv Therapeutics' stock symbol?
vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT."
How were vTv Therapeutics' earnings last quarter?
vTv Therapeutics Inc (NASDAQ:VTVT) released its quarterly earnings results on Thursday, November, 8th. The biotechnology company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.06. The biotechnology company earned $3.38 million during the quarter, compared to analysts' expectations of $2.06 million. View vTv Therapeutics' Earnings History.
When is vTv Therapeutics' next earnings date?
What price target have analysts set for VTVT?
5 analysts have issued twelve-month price objectives for vTv Therapeutics' shares. Their predictions range from $3.00 to $17.00. On average, they anticipate vTv Therapeutics' share price to reach $9.50 in the next year. This suggests a possible upside of 313.0% from the stock's current price. View Analyst Price Targets for vTv Therapeutics.
What is the consensus analysts' recommendation for vTv Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for vTv Therapeutics in the last year. There are currently 5 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for vTv Therapeutics.
What are Wall Street analysts saying about vTv Therapeutics stock?
Here are some recent quotes from research analysts about vTv Therapeutics stock:
- 1. Northland Securities analysts commented, "We anticipate details to be forthcoming. Trials: vTv Therapeutics indicated in its 10K filing (2/26 post-close) that the Company has initiated start-up activities for an adaptive P2/P3 trial evaluating azeliragon for treatment of mild Alzheimer’s disease (AD) patients with type 2 diabetes. We anticipate the P2 study will likely be comprised of ~100 subjects with mild AD and A1c levels at/above 6.5%, with ~6 month patient dosing. Based upon the previously released subgroup analysis of AD patients with type 2 diabetes in its large P3 STEADFAST Part A study (See Below), we believe a P2 trial w/ ~100 subjects and six month dosing would be sufficient to demonstrate clinical benefit to potentially support a P3 study." (2/27/2019)
- 2. According to Zacks Investment Research, "vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company's drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. " (2/9/2019)
Has vTv Therapeutics been receiving favorable news coverage?
Press coverage about VTVT stock has been trending somewhat positive on Monday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. vTv Therapeutics earned a news sentiment score of 1.1 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near future.
Who are some of vTv Therapeutics' key competitors?
Some companies that are related to vTv Therapeutics include Starpharma (SPL), Neptune Wellness Solutions (NEPT), Osmotica Pharmaceuticals (OSMT), Minerva Neurosciences (NERV), American Brivision (Holding) (ABVC), Geron (GERN), Harpoon Therapeutics (HARP), Gamida Cell (GMDA), IMV (IMV), Enochian Biosciences (ENOB), Monash IVF Group (MVF), Kodiak Sciences (KOD), Affimed (AFMD), Horizon Discovery Group (HZD) and Emblem (EMC).
What other stocks do shareholders of vTv Therapeutics own?
Who are vTv Therapeutics' key executives?
vTv Therapeutics' management team includes the folowing people:
- Mr. Jeffrey B. Kindler, Exec. Chairman (Age 63)
- Mr. Stephen L. Holcombe, Pres & CEO (Age 62)
- Mr. Rudy C. Howard CPA, B.A., CPA, Exec. VP & CFO (Age 61)
- Dr. Carmen Valcarce Ph.D., Chief Scientific Officer & Exec. VP
- Ms. Robin E. Abrams, Exec. VP & Gen. Counsel (Age 55)
When did vTv Therapeutics IPO?
(VTVT) raised $125 million in an IPO on Thursday, July 30th 2015. The company issued 7,800,000 shares at $15.00-$17.00 per share. Piper Jaffray and Stifel served as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.
Who are vTv Therapeutics' major shareholders?
vTv Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include D. E. Shaw & Co. Inc. (0.17%), Barclays PLC (0.07%) and Millennium Management LLC (0.03%). Company insiders that own vTv Therapeutics stock include Paul G Savas and Ronald O Perelman. View Institutional Ownership Trends for vTv Therapeutics.
Which major investors are selling vTv Therapeutics stock?
Which major investors are buying vTv Therapeutics stock?
VTVT stock was acquired by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc. and Barclays PLC. Company insiders that have bought vTv Therapeutics stock in the last two years include Paul G Savas and Ronald O Perelman. View Insider Buying and Selling for vTv Therapeutics.
How do I buy shares of vTv Therapeutics?
Shares of VTVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is vTv Therapeutics' stock price today?
One share of VTVT stock can currently be purchased for approximately $2.30.
How big of a company is vTv Therapeutics?
vTv Therapeutics has a market capitalization of $105.54 million and generates $12.43 million in revenue each year. The biotechnology company earns $-7,910,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis. vTv Therapeutics employs 52 workers across the globe.
What is vTv Therapeutics' official website?
How can I contact vTv Therapeutics?
vTv Therapeutics' mailing address is 4170 MENDENHALL OAKS PKWY, HIGH POINT NC, 27265. The biotechnology company can be reached via phone at 336-841-0300 or via email at [email protected]
MarketBeat Community Rating for vTv Therapeutics (NASDAQ VTVT)
MarketBeat's community ratings are surveys of what our community members think about vTv Therapeutics and other stocks. Vote "Outperform" if you believe VTVT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VTVT will underperform the S&P 500 over the long term. You may vote once every thirty days.
